Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TACE Combined With Lenvatinib and PD-1 Inhibitor for Spontaneous Rupture of Hepatocellular Carcinoma: a Prospective Multicenter Study

NCT06740370 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT06740370
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06740370 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TACE Combined With Lenvatinib and PD-1 Inhibitor for Spontaneous Rupture of Hepatocellular Carcinoma: a Prospective Multicenter Study
Lead sponsor
Sun Yat-sen University
Phase
Not applicable
Overall status
Recruiting
Start date
December 13, 2024
Completion date
August 30, 2026
Enrollment
32 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anti-pd1 antibody, hepatocellular carcinoma, lenvatinib, transcatheter arterial chemoembolization